Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

Jivadco (trastuzumab duocarmazine)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Byondis, Medac

Drug class:

HER2-targeted antibody-drug conjugate, DNA replication inhibitor

Related drugs:

‹

ado-trastuzumab emtansine (97)

fam-trastuzumab deruxtecan-nxki (90)

disitamab vedotin (27)

PF-06804103 (4)

MF-TTZ-MMAE (1)

inotuzumab ozogamicin (28)

gemtuzumab ozogamicin (24)

idarubicin (22)

bendamustine (12)

loncastuximab tesirine-lpyl (7)

rovalpituzumab tesirine (5)

PF-06647263 (0)

›

HER-2 positive	HER2 Positive Breast Cancer	HER-2 positive	HER2 Positive Breast Cancer	trastuzumab duocarmazine Sensitive: B - Late Trials trastuzumab duocarmazine Sensitive : B	trastuzumab duocarmazine Sensitive: B - Late Trials trastuzumab duocarmazine Sensitive : B
HER-2 underexpression	Breast Cancer	HER-2 underexpression	Breast Cancer	trastuzumab duocarmazine Sensitive: C3 – Early Trials trastuzumab duocarmazine Sensitive : C3	trastuzumab duocarmazine Sensitive: C3 – Early Trials trastuzumab duocarmazine Sensitive : C3
HR positive	HER2 Positive Breast Cancer	HR positive	HER2 Positive Breast Cancer	trastuzumab duocarmazine Sensitive: C3 – Early Trials trastuzumab duocarmazine Sensitive : C3	trastuzumab duocarmazine Sensitive: C3 – Early Trials trastuzumab duocarmazine Sensitive : C3
HER-2 underexpression	Hormone Receptor Positive Breast Cancer	HER-2 underexpression	Hormone Receptor Positive Breast Cancer	trastuzumab duocarmazine Sensitive: C3 – Early Trials trastuzumab duocarmazine Sensitive : C3	trastuzumab duocarmazine Sensitive: C3 – Early Trials trastuzumab duocarmazine Sensitive : C3
HER-2 overexpression	Breast Cancer	HER-2 overexpression	Breast Cancer	olaparib + niraparib + trastuzumab duocarmazine Sensitive: D – Preclinical olaparib + niraparib + trastuzumab duocarmazine Sensitive : D	olaparib + niraparib + trastuzumab duocarmazine Sensitive: D – Preclinical olaparib + niraparib + trastuzumab duocarmazine Sensitive : D
HER-2 underexpression	Ovarian Cancer	HER-2 underexpression	Ovarian Cancer	olaparib + niraparib + trastuzumab duocarmazine Sensitive: D – Preclinical olaparib + niraparib + trastuzumab duocarmazine Sensitive : D	olaparib + niraparib + trastuzumab duocarmazine Sensitive: D – Preclinical olaparib + niraparib + trastuzumab duocarmazine Sensitive : D